Avoiding unnecessary sentinel lymph node biopsy with the use of superparamagnetic iron oxide mapping agents (Magtrace®) in breast surgery.

BACKGROUND: Superparamagnetic iron oxide (SPIO) (Magtrace®) is a non-radioactive liquid tracer that can stay in the sentinel lymph nodes for 30 days. Injection of SPIO at time of primary breast surgery where upfront sentinel lymph node biopsy (SLNB) is not immediately indicated allows for a return to theatre if pathology then identifies invasive disease. SLNB is associated with paraesthesia, pain, seroma formation and lymphoedema risk. Hence, our study aims to assess the use of SPIO to avoid upfront SLNB in breast surgery for ductal carcinoma in situ (DCIS) and prophylaxis. METHODS: Retrospective single-centre study of consecutive patients who underwent injection of SPIO tracer at time of primary breast surgery to avoid upfront SLNB at Chris O'Brien Lifehouse, Sydney, NSW, Australia over a 10-month period. RESULTS: SPIO was injected 38 times, with 34 at time of mastectomy and four cases at time of wide local excision. The indication for surgery was DCIS in 18 cases, risk reduction in 17 cases and other indications in three patients. Six cases (15.8%) required delayed SLNB (D-SLNB) due to the finding of invasive disease on post-operative histopathology. All patients who underwent D-SLNB had nodes successfully localized with SPIO. CONCLUSION: In our cohort, 84.2% of cases were able to avoid upfront SLNB, and hence avoid the associated complications of SLNB. SPIO injection was successful in localizing the SLN in all cases at time of surgery for D-SLNB. This technique was safe with few associated complications.

Outcomes of adrenalectomy performed in regional New South Wales, Australia.

BACKGROUND: Centralization of subspeciality procedures in Australia is difficult due to a vast geographical span and in the appropriate patient group, surgery in regional centres should be considered. Our study reviews the safety of adrenalectomy performed at a low-volume regional centre in regards to length of hospital admission, operative time, complication rate and conversion to open rate. METHOD: A retrospective cross-sectional study was performed of consecutive patients undergoing laparoscopic or open adrenalectomy over a nine-year period (2012-2021) at Dubbo Base Hospital, a regional hospital in Western New South Wales, Australia. These operations were all performed by a single Urologist. RESULTS: Thirteen patients underwent adrenalectomy at our institution over the nine-year period. The mean age was 51.7 years (SD10.1). There were seven women (53.8%) and six men (46.2%). Seven patients were considered low risk, four patients were medium risk and two patients were high risk as per the Charlson Comorbidity Index. All of our patients were overweight, with mean body mass index of 34.6 (SD 6.9). Mean operating time was 133.5 min (SD 36.3) and mean length of stay was 3.8 days (SD 2.2). There was one conversion to open (8.3%). Three patients (23.1%) had complications, of these complications, one was Clavien-Dindo grade II, and one was Clavien-Dindo grade IIIb. There were no mortalities. CONCLUSION: Our outcomes demonstrate that adrenalectomy in our low volume regional centre is safe with comparable outcomes of operative time, length of hospital stay and complication rate with other centres.

Complications Arising From Perioperative Anticoagulant/Antiplatelet Therapy in Major Colorectal and Abdominal Wall Surgery.

BACKGROUND: Postoperative hemorrhage and thromboembolism are recognized complications following colorectal and abdominal wall surgery, but accurate documentation of their incidence, trends, and outcomes is scant. This is relevant given the increasing number of surgical patients with cardiovascular comorbidity on anticoagulant/antiplatelet therapy. OBJECTIVE: This study aims to characterize trends in the use of anticoagulant/antiplatelet therapy among patients undergoing major colorectal and abdominal wall surgery within the past decade, and to assess rates of, outcomes following, and risk factors for hemorrhagic and thromboembolic complications. DESIGN AND SETTING: This is a retrospective cross-sectional study conducted at a single quaternary referral center. PATIENTS: Patients who underwent major colorectal and abdominal wall surgery during three 12-month intervals (2005, 2010, and 2015) were included. MAIN OUTCOME MEASURES: The primary outcomes measured was the rate of complications relating to postoperative hemorrhage or thromboembolism. RESULTS: One thousand one hundred twenty-six patients underwent major colorectal and abdominal wall surgery (mean age, 61.4 years (SD 16.3); 575 (51.1%) male). Overall, 229 (21.7%) patients were on anticoagulant/antiplatelet agents; there was an increase in the proportion of patients on clopidogrel, dual antiplatelet therapy, and novel oral anticoagulants over the decade. One hundred seven (9.5%) cases were complicated by hemorrhage/thromboembolism. Aspirin (OR, 2.22; 95% CI, 1.38-3.57), warfarin/enoxaparin (OR, 3.10; 95% CI, 1.67-5.77), and dual antiplatelet therapy (OR, 2.99; 95% CI, 1.37-6.53) were most implicated with complications on univariate analysis. Patients with atrial fibrillation (adjusted OR 2.67; 95% CI, 1.47-4.85), ischemic heart disease (adjusted OR, 2.14; 95% CI, 1.04-4.40), and mechanical valves (adjusted OR, 7.40; 95% CI 1.11-49.29) were at increased risk of complications on multivariate analysis. The severity of these events was mainly limited to Clavien-Dindo 1 (n = 37) and 2 (n = 46) complications. LIMITATIONS: This is a retrospective study with incomplete documentation of blood loss and operative time in the early study period. CONCLUSIONS: One in ten patients incurs hemorrhagic/thromboembolic complications following colorectal and abdominal wall surgery. "High-risk" patients are identifiable, and individualized management of these patients concerning multidisciplinary discussion and critical-care monitoring may help improve outcomes. Prospective studies are required to formalize protocols in these "high-risk" patients. See Video Abstract at http://links.lww.com/DCR/A747.